Bionomics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch Bionomics and buy or sell other stocks, ETFs, and their options commission-free!

About BNOX

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. 

CEO
Spyridon Papapetropoulos, MD, PhD
CEOSpyridon Papapetropoulos, MD, PhD
Employees
8
Employees8
Headquarters
Burlington, Massachusetts
HeadquartersBurlington, Massachusetts
Founded
Founded
Employees
8
Employees8

BNOX Key Statistics

Market cap
11.57M
Market cap11.57M
Price-Earnings ratio
-0.26
Price-Earnings ratio-0.26
Dividend yield
—
Dividend yield—
Average volume
8.85M
Average volume8.85M
High today
—
High today—
Low today
—
Low today—
Open price
—
Open price—
Volume
0.00
Volume0.00
52 Week high
$21.40
52 Week high$21.40
52 Week low
$2.12
52 Week low$2.12
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.